ECTRIMS 2021 – Late Breaking News ePoster

C., Chien,; V. Cruz, Silva,; E., Geiter,; H., Zimmermann,; S., Specovius,; F. C., Oertel,; D. B., Bichuetti,; M., Idagawa,; A., Altintas,; U., Tanriverdi,; S., Siritho,; L., Pandit,; A., Dcunha,; M. J., Sa,; R., Figueiredo,; C., Tongco,; P., Qian,; I., Lotan,; V., Khasminsky,; M., Hellmann,; H., Stiebel-Kalish,; D., Rotstein,; L., Waxman,; D., Ontaneda,; K., Nakamura,; H., Abboud,; M. O., Subei,; Y., Mao-Draayer,; J., Havla,; N., Asgari,; P., Skejo,; I., Kister,; Z., Rimler,; A., Reid,; M., Ringelstein,; S., Broadley,; S., Arnett,; B., Marron,; A., Jolley,; M., Wunderlich,; S., Green,; L., Cook,; M. R., Yeaman,; T. J., Smith,; A. U., Brandt,; J., Wuerfel,; F., Paul,; GICC, NMOSD,

doi:10.1177/13524585211047080

Public

ECTRIMS 2021 – Late Breaking News ePoster

Published in Multiple Sclerosis Journal • Oct 1, 2021

Authors:

Chien, C.

Silva, V. Cruz

Geiter, E.

Abstract

Objective: To compare humoral and T-cell responses to COVID- 19 vaccines in 400 MS patients who were on Ocrelizumab ('OCR') v. other disease-modifying therapies ('non-OCR') at the time of vaccination. Introduction: Peripheral B-cell depletion with anti-CD20 therapies attenuates humoral responses to ...

Subject

Medicine

Immune system

Immunology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!